WitrynaAlthough the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. … Witryna13 lut 2024 · In the IMPower 133 trial 3, the efficacy of atezolizumab in combination with carboplatin and etoposide was assessed in patients with ES-SCLC. In this phase III, placebo-controlled RCT,...
IMpower133 Trial for Extensive-Stage SCLC - OncLive
Witryna11 cze 2024 · IMpower133 trial included 403 patients with extensive-stage SCLC and tested the benefit of adding atezolizumab to standard carboplatin–etoposide chemotherapy in the first-line setting. Addition of atezolizumab to combined chemotherapy significantly improved median PFS (5.2 vs 4.3 months) and OS (12.3 … WitrynaThe IMpower133 trial evaluated the efficacy and safety of adding atezolizumab or placebo to first-line treatment with carboplatin and etopo-side in patients with … news related to jsw steel
Small cell lung cancer patients treated with immune checkpoint ...
WitrynaThe meaning of IMPOWER is obsolete variant of empower. Love words? You must — there are over 200,000 words in our free online dictionary, but you are looking for one … Witryna10 kwi 2024 · Background: We aimed to evaluate the prognostic value of imaging biomarkers on 18F-FDG PET/CT in extensive-stage small-cell lung cancer (ES-SCLC) patients undergoing first-line chemo-immunotherapy. Methods: In this multicenter and retrospective study, we considered two cohorts, depending on the type of first-line … WitrynaClinical trial identification. NCT02763579. Editorial acknowledgement. Medical writing assistance for this abstract was provided by Kia C. E. Walcott, PhD, of Health Interactions. Legal entity responsible for the study. F. Hoffmann-La Roche, Ltd. Funding. F. Hoffmann-La Roche, Ltd. Disclosure midge cycle